Group items tagged

Mice injected with cancer cells experienced significantly elevated levels of C-reactive protein, white blood cells, and lipid peroxidation compared with control mice. These levels were reduced in animals that received cisplatin and/or DHA. While treatment with 125 mg/kg DHA inhibited tumor growth by 38 percent compared to untreated animals, 250 mg/kg suppressed tumor growth by 79 percent, which was a greater effect than that of cisplatin alone (which was associated with a 55 percent reduction). The combination of DHA and cisplatin resulted in an 81 percent inhibition of growth, while reducing elevated white blood cell levels (leukocytosis) to normal levels. Treatment with the higher dose of DHA alone was associated with a similar reduction in white blood cells, which, when elevated, are associated with tumor growth. A strong relationship was observed between tumor growth and white blood cell levels as well as C-reactive protein levels. In another experiment with rats treated with cisplatin, the addition of 250 mg/kg DHA prevented lethal kidney toxicity in 88 percent of the animals that received it, while none of the rats that received cisplatin alone survived.

The vitamin K dependant protein osteocalcin may have a positive effect on reducing obesity and diabetes, suggests a new study with mice.\nResearchers writing in the journal Cells studied the effect bone cells have in energy regulation, and found that osteocalcin plays a key role in regulating insulin activity.

Creative Diagnostics has invented novel immunization Magic™ Adjuvants specifically designed for rapid production of high titers antibodies in mice (Magic™ Mouse Adjuvant) and human (Magic™ Human Adjuvant). Our Magic™ Mouse Adjuvant is by far the most efficient mouse adjuvant for all types of immunogens tested.

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth.\nBuzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB. Cancer Res. 2007 Jul 15;67(14):6745-52. PMID: 17638885 doi: 10.1158/0008-5472.CAN-06-4447